Shandong Boan Biotechnology Co., Ltd (HKG: 6955), based in China, has announced a licensing agreement with fellow Chinese firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its in-house developed long-acting monoclonal antibody (mAb) BA2101. According to the agreement, Joincare will obtain exclusive rights to develop, regulate, and commercialize BA2101 in mainland China for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Boan will retain all rights to the drug for non-respiratory indications in mainland China and all rights for all indications outside of mainland China.
Joincare will make an undisclosed upfront payment to Boan, as well as pay development and sales milestone payments and royalties on sales. Joincare will also cover the costs for clinical study and development activities related to BA2101 for respiratory diseases in mainland China.
BA2101 is an innovative long-acting human monoclonal IgG4 antibody that targets the interleukin-4 receptor subunit α (IL-4R α). Administered subcutaneously with an expected four-week administration cycle, the drug can inhibit both the IL-4 and IL-13 signal pathways, regulate Th2 type inflammation, reduce eosinophil content and IgE levels, and treat allergic diseases caused by Th2 type inflammation. The intended indications for BA2101 include atopic dermatitis, asthma, chronic sinusitis with nasal polyps, prurigo nodosum, chronic spontaneous urticaria, and more.- Flcube.com
